On October 14, Mindray released the first three quarters of the revenues forecast. The company is expected to achieve the operating income of 14.855 billion yuan to 16.093 billion yuan in the first three quarters of 2020, a year-on-year growth of 20% to 30%;the net profit attributable to shareholders of listed companies is expected to be 4.956 billion yuan to 5.323 billion yuan, a year-on-year increase of 35% to 45%.

 At the same time, Mindray disclosed the third quarter of the performance forecast, it is expected to achieve operating income of 5.009 billion yuan to 5.426 billion yuan in the third quarter, a year-on-year increase of 20% to 30%;it is estimated that the net profit attributable to the shareholders of the listed company will be 1.758 billion yuan ~1.888 billion yuan, with a year-on-year increase of 35%-45%.

In the third quarter, due to the continuous spread of COVID-19 around the world, the international market demand for relevant anti-COVID-19 products such as monitors, ventilators, infusion pumps, covid-19 antibody reagents, portable color ultrasound and mobile DR is still at a high level, and the influence of the company's products is also increasing;at the same time, in vitro diagnostic reagents and other routine business in Chinese market gradually returned to normal growth, so that the company continued to maintain a stable revenue growth during the reporting period.At the same time, the company continued to strengthen internal management and improve operating efficiency. During the epidemic, online promotion and other means were adopted for marketing promotion. Operating expenses such as travel expenses were effectively controlled, and the net profit continued to show a healthy and strong growth.

The international epidemic situation is still unclear, and the demand for anti-epidemic products in the international market is still maintained. In order to cope with the second wave of the epidemic, some European countries have begun to increase the deployment of their medical systems;in addition to the gradual resumption of routine business, in order to prevent the second outbreak of the epidemic and strengthen the construction of the treatment capacity for major epidemics, local governments have also launched plans to strengthen the weak links in medical treatment. In view of the company's brand influence and recognition in China and foreign markets have been greatly enhanced, it’s expected to usher in better opportunities for development in the future.At the same time, the company continues to strengthen internal management and operational efficiency improvement, so that the company's operating income and net profit to achieve stable and healthy growth.

On October 13, Kehua announced that the company expects the net profit of the first three quarters of 2020 to be 354 million yuan to 417 million yuan, a year-on-year growth of 70% to 100%;the net profit for the third quarter is expected to be 161 million yuan to 224 million yuan, up 132% to 222% year on year.

During the reporting period, in the face of the global COVID-19 outbreak, the company gave full play to its advantages in product research and development and channel terminal in the field of molecular diagnosis for many years, so as to further promote the sales growth of molecular clinical products in the terminal market.During the reporting period, the sales revenue of nucleic acid extraction reagent and instrument produced by the company in molecular diagnostic business and nucleic acid detection instrument all achieved a substantial increase.